ArticleScientific reports2026

The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study.

Ahmet Oruç et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.